Brief: Cardiff Oncology Provides Clinical Update On Phase 2 Randomized Second-Line ONSEMBLE Trial In Patients With RAS-mutated mCRC
29/02/2024 22:51
Feb 29 (Reuters) - Cardiff Oncology Inc CRDF.O :
* CARDIFF ONCOLOGY PROVIDES CLINICAL UPDATE ON PHASE 2
RANDOMIZED
SECOND-LINE ONSEMBLE TRIAL IN PATIENTS WITH RAS-MUTATED MCRC
* CARDIFF ONCOLOGY:CLINICAL DATA REPEATS EFFICACY FINDINGS
OF
ONVANSERTIB IN BEV NAÏVE PATIENTS SEEN IN CO'S EARLIER PHASE
1B/2 KRAS-MUTATED MCRC TRIAL
Source text for Eikon: ID:nGNXK0H19
Further company coverage: CRDF.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering